clinical trial · NCT06936527
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
NovaOnco Therapeutics Co., Ltd.·phase2·enrolling by invitation·n = 102
Colorectal CancerMetastatic Colorectal Cancer With RAS MutationDrug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIDrug: XS-03Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
brief summary
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
started
May 23, 2025
primary completion
Apr 30, 2028
completion
Jul 30, 2028
last updated
Sep 3, 2025
official title
An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol